EP2098248A1 — Combination of anticholinergics, glucocorticoids and beta2-agonists for the treatment of inflammatory diseases
Assigned to Meda Pharma GmbH and Co KG · Expires 2009-09-09 · 17y expired
What this patent protects
The invention relates to novel combinations based on anticholinergics, β 2 -adrenoceptor agonists, and glucocorticoids, process for production and its use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmo…
USPTO Abstract
The invention relates to novel combinations based on anticholinergics, β 2 -adrenoceptor agonists, and glucocorticoids, process for production and its use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmonary diseases (COPD) or rheumatic or autoimmune diseases.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.